Oncolytics Biotech (ONC) Stock Price, News & Analysis

Company Overview

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Key Stats

• Today's Range: C$14.90 to C$14.90
• 50-Day Range: C$14.90 to C$14.90
• 52-Week Range: C$0.44 to C$2.08
• Volume: 280 shs
• Average Volume: 169,589 shs
• Market Capitalization: C$1.50 billion
• P/E Ratio: N/A
• Dividend Yield: 0.31%
• Price Target: N/A
• Consensus Rating: Strong Buy

Oncolytics Biotech Stock Analysis - MarketRank™

Oncolytics Biotech scored higher than 0% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.0 / 5
• Analyst Rating: Strong Buy

Amount of Analyst Coverage

Oncolytics Biotech has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Oncolytics Biotech is -40.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Oncolytics Biotech is -40.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for ONC.

Dividend

• Score: 0.0 / 5
• Dividend Strength: Weak

Dividend Yield

Oncolytics Biotech has a dividend yield of 0.31%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Oncolytics Biotech does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Oncolytics Biotech this week, compared to 2 articles on an average week.

Search Interest

7 people have searched for ONC on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Oncolytics Biotech insiders have not sold or bought any company stock.

Percentage Held by Insiders

3.82% of the stock of Oncolytics Biotech is held by insiders.

Percentage Held by Institutions

0.07% of the stock of Oncolytics Biotech is held by institutions.

Company Calendar

• Last Earnings: 11/12/2024
• Today: 6/15/2026

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: TSE:ONC
• CIK: N/A
• Web: www.oncolyticsbiotech.com
• Phone: +1-403-6707380
• Fax: N/A
• Employees: 29
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): C($0.37)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -C$27.66 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -337.21%
• Return on Assets: -71.33%

Debt

• Debt-to-Equity Ratio: 14.58
• Current Ratio: 2.88
• Quick Ratio: 8.86

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: C$3.53 per share
• Price / Cash Flow: 4.22
• Book Value: C$0.07 per share
• Price / Book: 222.68

Miscellaneous

• Outstanding Shares: 100,361,000
• Free Float: N/A
• Market Cap: C$1.50 billion
• Optionable: Not Optionable
• Beta: 0.80